Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.45
Bid: 7.00
Ask: 7.90
Change: 0.00 (0.00%)
Spread: 0.90 (12.857%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 7.45
CAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Response to announcement from Consort Medical

2 Jul 2018 13:07

RNS Number : 2802T
Carclo plc
02 July 2018
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

FOR IMMEDIATE RELEASE 2 Jul 2018

Response to announcement from Consort Medical plc

Carclo plc ("Carclo" or the "Company") notes today's announcement by Consort Medical plc ("Consort") and confirms that it received a highly preliminary indicative non-binding all paper proposal for the Company from Consort on 29 May 2018 (the "Proposal"). The Proposal valued each Carclo share at 116 pence to be satisfied in new Consort shares.

The Board of Carclo (the "Board") discussed the Proposal, together with its advisers, and concluded that the Proposal in no way reflected the fundamental value of the Company. Consequently, the Board was unanimous in rejecting this opportunistic approach on 01 June 2018.

The Board is confident in Carclo's standalone strategy and growth prospects and believes the Company's long-term value should not be affected by the challenges which management are addressing. This process will be strengthened by the announced appointments of Mark Rollins as Chairman, Sarah Matthews-DeMers as Group Finance Director, and Joe Oatley as a Non-Executive Director, all of whom take up their respective roles this month.

The Board believes the focus on the Company's two core divisions, Carclo Technical Plastics ("CTP") and LED Technologies, will deliver a successful future for the Group and notes Consort's primary interest appears to be only in the CTP division.

We also note the statement that Carclo has rejected requests from Consort for a meeting. Carclo has consistently made it clear that should Consort come forward with a proposal which the Board would be minded to recommend to shareholders it would, of course, be receptive to a meeting.

This statement is being made by the Company without the prior agreement of Consort and there can be no certainty that an offer will be forthcoming.

The person responsible for arranging the release of this announcement on behalf of Carclo is Richard Ottaway, Company Secretary.

For more information please contact:

Rothschild (Carclo's Financial Adviser) Tel: +44 (0)113 200 1900

Stephen Griffiths

Notice relating to Financial Adviser

N M Rothschild & Sons Limited ("Rothschild"), which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting as exclusive financial adviser to Carclo and no one else in connection with the subject matter of this announcement. In connection with the subject matter of this announcement, Rothschild, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or any other matter referred to therein.

Disclosure requirements of the Takeover Code (the "Code")

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

Rule 26.1 disclosure

In accordance with Rule 26.1 of the Code, a copy of this announcement will be available at www.carclo.co.uk by no later than 12 noon (London time) on 3 July 2018. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Rule 2.9 information

In accordance with Rule 2.9 of the Code, Carclo confirms that as at the close of business on 29 June 2018 its issued share capital consisted of 73,286,918 ordinary shares of 5 pence each. The International Securities Identification Number for Carclo's ordinary shares is GB0001751915.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RSPBDGDRXGGBGID
Date   Source Headline
28th Feb 20247:00 amRNSDirectorate Change
14th Feb 20247:00 amRNSStrategic Consolidation & Tucson Facility Closure
9th Feb 20241:15 pmRNSHolding(s) in Company
29th Jan 202411:09 amRNSDirectorate Change
23rd Jan 20244:48 pmRNSHolding(s) in Company
6th Dec 202310:53 amRNSHolding(s) in Company
30th Nov 20237:00 amRNSHalf-year Report
16th Nov 20237:00 amRNSNotice of Interim Results & Investor Presentation
25th Oct 20233:16 pmRNSCarclo Strategic Decision to Close Derry Facility
22nd Sep 20237:00 amRNSDirector/PDMR Shareholding
31st Aug 20234:01 pmRNSResult of AGM
31st Aug 20237:00 amRNSTrading Update
21st Aug 20231:09 pmRNSDirectorate Change
31st Jul 202311:42 amRNSAnnual Financial Report
18th Jul 20237:00 amRNSBanking covenant update
12th Jul 20237:00 amRNSFinal Results
7th Jul 20237:00 amRNSNotice of Investor Meet Presentation
23rd Jun 20237:00 amRNSBanking covenant adjustment
21st Jun 20231:08 pmRNSNotice of Results
30th May 202310:07 amRNSUpdate on contract cancellation
17th May 20238:46 amRNSHolding(s) in Company
12th May 20239:38 amRNSHolding(s) in Company
14th Apr 20237:00 amRNSTrading Statement
31st Mar 202312:50 pmRNSBanking Covenant update
9th Mar 20239:56 amRNSHolding(s) in Company
24th Feb 20237:00 amRNSDirectorate Change
6th Jan 20234:17 pmRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20221:15 pmRNSDirector/PDMR Shareholding
16th Dec 20221:11 pmRNSDirector/PDMR Shareholding
16th Dec 20221:10 pmRNSDirector/PDMR Shareholding
15th Dec 20227:00 amRNSTrading Update
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 20229:44 amRNSContract Cancellation
6th Dec 20226:29 pmRNSHolding(s) in Company - Replacement
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
30th Nov 20227:00 amRNSHalf-year Report
15th Nov 20227:05 amRNSNotice of Interim Results & Investor Presentation
15th Nov 20227:00 amRNSDirectorate Change
7th Nov 20227:00 amRNSBoard Changes
18th Oct 20227:00 amRNSTrading Update
13th Oct 20221:22 pmRNSHolding(s) in Company
6th Oct 20221:05 pmRNSAppointment of Chief Executive Officer
16th Sep 20223:16 pmRNSHolding(s) in Company
5th Sep 20227:00 amRNSTripartite Financing Agreement Secured

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.